Search Result "Daclatasvir"
Effect of Atorvastatin on Single Oral Pharmacokinetics and Safety of Daclatasvir inRats: Emphasis on P-glycoprotein and Cytochrome P450
Journal: Current Drug Metabolism
Volume: 23 Issue: 6 Year: 2022 Page: 484-495
Author(s): Heba A. Elbadawy,Sara A. Wahdan
Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A
Journal: Current Medicinal Chemistry
Volume: 21 Issue: 12 Year: 2014 Page: 1391-1404
Author(s): I. Gentile,F. Borgia,N. Coppola,A.R. Buonomo,G. Castaldo,G. Borgia
The Role of CYPs and Transporters in the Biotransformation and Transport ofthe Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, andBeclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions onSafety and Efficacy
Journal: Current Drug Metabolism
Volume: 25 Issue: 2 Year: 2024 Page: 96-109
Author(s):
Is Daclatasvir a Suitable Substitute for Amphotericin B in the Treatmentof Mucormycosis when Amphotericin B is Scarce?
Journal: Current Drug Research Reviews
Volume: 16 Issue: 1 Year: 2024 Page: 5-10
Author(s): Lappathai Habib Mohamed Thameemul Ansari
Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients
Journal: Current Drug Safety
Volume: 15 Issue: 1 Year: 2020 Page: 53-60
Author(s): Lamiaa N. Abdelaty,Ahmed A. Elnaggar,Amira A. Said,Raghda R.S. Hussein
Daclatasvir and Sofosbuvir Mitigate Hepatic Fibrosis Through Downregulation of TNF-α / NF-κB Signaling Pathway
Journal: Current Molecular Pharmacology
Volume: 13 Issue: 4 Year: 2020 Page: 318-327
Author(s): Sherin Zakaria,Alaa E. El-Sisi
Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients
Journal: Infectious Disorders - Drug Targets
Volume: 20 Issue: 1 Year: 2020 Page: 43-48
Author(s): Engy A. Wahsh,Amal K. Hussein,Ahmed A. Gomaa,Mohamed A. Baraka,Mohie Al-deen Abead
Comparative Real Life Egyptian Experience of the Combination of SofosbuvirPlus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic PatientsInfected with HCV Genotype 4
Journal: Current Drug Safety
Volume: 18 Issue: 2 Year: 2023 Page: 207-213
Author(s):
Quality by Design-driven Analytical Method: A Quality RiskManagement-Based Liquid Chromatography Method for Daclatasvir andCharacterization of its Putative Degradants by LC-MS/MS
Journal: Current Pharmaceutical Analysis
Volume: 20 Issue: 3 Year: 2024 Page: 188-201
Author(s):
Study of Adverse Drug Effects of Direct-Acting Antivirals for Chronic HCV Infection at Fayoum Governorate, Egypt - A Pharmacovigilance Study
Journal: Current Drug Safety
Volume: 13 Issue: 3 Year: 2018 Page: 187-195
Author(s): Eman I. Ahmed,Wafaa Y. Abdel Wahed,Essam A. Hassan,Tarek I. Ahmed